Status: Excluded | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA903: Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer |
|
Medicine details |
|
Medicine name | darolutamide (Nubeqa®) |
Formulation | 300mg film-coated tablet |
Reference number | 3330 |
Indication | Treatment of patients with metastatic, hormone-sensitive prostate cancer |
Company | Bayer Healthcare Pharmaceuticals |
BNF chapter | Malignant disease & immunosuppression |
Submission type | N/A |
Status | Excluded |
Date of issue | 01/12/2022 |
NICE guidance |